Kodak: KRIP Walking To The Bank

Eastman Kodak (KODK) is terminating its overfunded U.S. defined benefit pension plan (KRIP), a move projected to yield approximately $500 million in net proceeds by year-end 2025, comprising $300 million cash and $200 million in illiquid assets. This capital infusion is critical for paying down a significant portion of its Term Loan, thereby alleviating a 'going concern' warning and substantially reducing interest expenses, which currently match its year-to-date net loss. The financial flexibility gained is intended to support the company's strategic pivot towards pharmaceutical manufacturing and battery technology, with a key preferred stockholder recently converting their position at a premium, signaling support for this transition despite ongoing weakness in its core printing plate business and declining operational EBITDA.

Analysis

Eastman Kodak is undertaking a critical balance sheet restructuring by terminating its overfunded pension plan (KRIP), a move projected to yield approximately $500 million in net proceeds by the end of 2025. This capital infusion is earmarked to significantly pay down its Term Loan, with recent amendments now targeting a reduction to a $100 million balance, which will alleviate the current 'going concern' warning and materially reduce cash burn, as interest expenses have been commensurate with the company's year-to-date net loss. This financial maneuver is supported by a key stakeholder, evidenced by the holder of Series C Preferred stock converting their entire position at a premium price of $8.15 per share, eliminating a $123 million liability. However, this financial lifeline is set against a backdrop of deteriorating operational performance. Year-to-date operational EBITDA has fallen 20% to $12 million, indicating that protective tariffs have failed to stabilize the core printing plate business. The company's valuation, with a market capitalization over $600 million on a declining $24 million run-rate EBITDA, appears to heavily price in future success from its strategic pivot into pharmaceuticals and battery technology, ventures which are currently pre-revenue and speculative.

Key Decisions for Investors

• Investors should monitor the successful completion of the KRIP termination by year-end 2025, as the receipt of the projected $500 million is the primary catalyst for removing the going concern warning and de-leveraging the balance sheet.
• Given the 20% decline in operational EBITDA despite tariff protections, consider the stock a speculative investment on the unproven pharmaceutical and battery initiatives rather than a value play on its legacy business.
• Evaluate the risk-reward profile in light of the valuation, as the current market cap appears to price in significant success from new ventures, while the core business continues to weaken.
• Note the Series C preferred conversion at an $8.15 premium as a strong signal of insider confidence, but remain aware of the potential for future dilution from the remaining $100 million in Series B preferred stock and the untapped $100 million ATM facility.